Recent Updates
Recently added Catalysts
BLRX Positive Sentiment

BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

Friday, May 22, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: BioLineRx and Hemispherian AS announced that two abstracts on GLIX1 will be presented at the ASCO 2026 Annual Meeting. This collaboration highlights their commitment to developing innovative therapies in oncology. The meeting will take place from May 29 to June 2, 2026, in Chicago, IL.
Price reaction · baseline $2.86 (2026-05-21 close) · hit after-hours · clean, no other BLRX news in the window
day 0 close
+7%
day 1
+10.5%
day 3 · peak
+25.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • BioLineRx and Hemispherian AS are collaborating on promising oncology therapies.
  • GLIX1 data will be featured at a prestigious conference.
  • The ASCO meeting provides a platform for significant exposure.

Full Press Release Details

TEL AVIV, Israel and OSLO, Norway,May 22, 2026/PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that two abstracts featuring GLIX1 will be published at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, which is being held May 29-June 2, 2026, in Chicago, IL.

Frequently Asked Questions

What is GLIX1?

GLIX1 is a novel therapeutic being developed by BioLineRx and Hemispherian for oncology.

When is the ASCO 2026 Annual Meeting?

The ASCO 2026 Annual Meeting will be held from May 29 to June 2, 2026.

Where will the ASCO 2026 meeting take place?

The ASCO 2026 meeting will take place in Chicago, IL.

Who are the companies involved in the GLIX1 data presentation?

The companies involved are BioLineRx and Hemispherian AS.

ShareAdd on Google
Tags: BLRX Viatris Investor Conferences Healthcare BioLineRx Hemispherian GLIX1 oncology ASCO
Last updated: May 22, 2026

Biotech snapshot

Lead asset
BL-8040/kg+ G-CSFPhase 3
Multiple Myeloma →